Question 1

How big is the Global Oligonucleotide CDMO market?

Accepted Answer

According to Value Market Research, the global Global Oligonucleotide CDMO market size was estimated at USD 3.45 Billion in 2025 and is expected to reach USD 4.21 Billion in 2026.

Question 2

What is the Global Oligonucleotide CDMO market growth?

Accepted Answer

The global Global Oligonucleotide CDMO market is expected to grow at a CAGR of 21.96% from 2026-2034 to reach USD 20.60 Billion by 2034.

Question 3

Which region holds the highest share in the Global Oligonucleotide CDMO market?

Accepted Answer

North America held the highest share in the global Global Oligonucleotide CDMO market.

Question 4

How is the Global Oligonucleotide CDMO market segmented in the report?

Accepted Answer

The Global Oligonucleotide CDMO market is segmented By Service Type (Contract Manufacturing (Clinical Stage, Commercial Stage), Contract Development, Analytical and Quality Control Services, Regulatory and CMC Support Services), By Oligonucleotide Type (Antisense Oligonucleotides, Small Interfering RNA, Guide RNA, Aptamers, Other Oligonucleotide Types), By Application (Therapeutic Applications (Rare Diseases, Oncology, Neurology, Cardiometabolic Diseases, Infectious Diseases), Research Applications, Diagnostic Applications, Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostic Companies, Academic & Research Institutes, Gene Therapy & Cell Therapy Developers, Other End Users).

Question 5

Which segment accounted for the largest oligonucleotide CDMO market share?

Accepted Answer

The therapeutic applications segment captured 57.62% of the market revenue in 2025, driven by increasing clinical development, regulatory approvals, and rising demand for oligonucleotide-based therapies targeting oncology, rare diseases, and genetic disorders.

Question 6

What are the factors driving the oligonucleotide CDMO market?

Accepted Answer

Key drivers include the growing adoption of oligonucleotide therapeutics, increasing outsourcing by pharmaceutical and biotechnology companies, expanding RNA-based drug development pipelines, rising regulatory approvals for nucleic acid therapies, and continuous investment in advanced manufacturing technologies that improve scalability, quality, and commercialization efficiency.

Question 7

Who are the key players in the Global Oligonucleotide CDMO market?

Accepted Answer

Some key players include Agilent Technologies Inc., Ajinomoto Co. Inc., Almac Group Limited, Asymchem Laboratories (Tianjin) Co. Ltd. and Bachem Holding AG.